On October 2, 2025, Andreas Argyrides, an analyst at Oppenheimer, released a report maintaining an "Outperform" rating for Monopar Therapeutics (MNPR, Financial). Alongside this rating, Oppenheimer raised its price target from $77.00 to $115.00, indicating a notable increase of 49.35%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.